CSIMarket


Jazz Pharmaceuticals Plc  (JAZZ)
Other Ticker:  
 


 

Jazz Pharmaceuticals Plc

JAZZ's Financial Statements and Analysis



Jazz Pharmaceuticals Plc reported in the forth quarter of 2023 net earnings per share of $1.20 an improvement compare to net loss per share of $-4.75 recorded a year ago and decline of -43.71 % from $2.14 earned in III. Quarter (Sep 30 2023).


forth quarter of 2023
Earnings Per Share Revenues
$ 1.2 $  1,012 Mill
$+5.95     $-236M     -18.92 %



Jazz Pharmaceuticals Plc's Revenue fell by -18.92 % in forth quarter of 2023 (Dec 31 2023) year on year, to $1,012 million and advanced by 4.09 % sequentially.


Jazz Pharmaceuticals Plc is

More on JAZZ's Income Statement



Jazz Pharmaceuticals Plc's net income of $94.154 million in the forth quarter of 2023 increased from net loss of $-341.353 million IV. Quarter a year ago.

Sequentially net earnings fell by -35.87 % from net income of $146.820 million realized in previous quarter.

More on JAZZ's Growth

Jazz Pharmaceuticals Plc Inventories
Inventories declined by -16.39 % to $597.04 million from IV. Quarter a year ago, sequentially inventories fell by -2.42 %. JAZZ's Cash flow In the forth quarter of 2023 company's net cash flow was $171 million, capital expenditures fell by -9.3787.72%, to $-10 millions compare to same quarter a year ago

More on JAZZ's Cash flow Statement


Jazz Pharmaceuticals Plc does not pay out common stock dividend.

In trailing twelve-month period Jazz Pharmaceuticals Plc earned $ 16.06 cash per share, on a free-cash flow basis 272.16 % of net earning per share.

Book value grew by 12.27 % sequentially to $54.95 per share, 95.66% of net income per share in trailing twelve-month period were contributed to shareholder value.
Tangible Book value grew to $ -50.50 per share from $ -50.97.

Company repurchased 3.29 million shares or 4.61 % in Dec 31 2023.
Interest Coverage Ratio was 2.03. Debt Coverage Ratio was 0.1.

More on JAZZ's Dividends

 Market Capitalization (Millions) 8,020
 Shares Outstanding (Millions) 68
 Total Debt (Millions $) 5,713
 Revenue (TTM) (Millions $) 3,834
 Net Income (TTM) (Millions $) 415
 Cash Flow (TTM) (Millions $) 625
 Capital Exp. (TTM) (Millions $) -24
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Employees (TTM) $ 1,720




Jazz Pharmaceuticals Plc does not pay out common stock dividend.

In trailing twelve-month period Jazz Pharmaceuticals Plc had $ 16.06 cash flow per share, on a free-cash flow basis 272.16 % of net earning per share.

Book value grew by 12.27 % sequentially to $54.95 per share, 95.66% of net income per share in trailing twelve-month period were contributed to shareholder value.
Tangible Book value grew to $ -50.50 per share from $ -50.97.

Company repurchased 3.29 million shares or 4.61 % in Dec 31 2023.
Interest Coverage Ratio was 2.03. Debt Coverage Ratio was 0.1.

More on JAZZ's Balance Sheets

 Market Capitalization (Millions) 8,020
 Shares Outstanding (Millions) 68
 Total Debt (Millions $) 5,713
 Revenue (TTM) (Millions $) 3,834
 Net Income (TTM) (Millions $) 415
 Cash Flow (TTM) (Millions $) 625
 Capital Exp. (TTM) (Millions $) -24
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Employees (TTM) $ 1,720
   


  News about Jazz Pharmaceuticals Plc Earnings

Jazz Pharmaceuticals Plc Faces Uncertainty Despite Positive Profit Numbers

Jazz Pharmaceuticals Plc: Weak Financial Performance Raises Concerns
Jazz Pharmaceuticals Plc, a major pharmaceutical preparations company, reported surprisingly positive profit numbers for the financial fourth quarter of 2023. However, a closer analysis reveals a much bleaker outlook for the company. Profits turned positive at $1.20 per share compared to a staggering loss of $4.75 per share in the same quarter a year ago. Although this may seem like a remarkable improvement, it is important to note that profits plummeted by a significant -43.71% from $2.14 per share in the preceding quarter.
The company's revenue also presents a cause for concern. It decreased substantially by -18.925% to $1.01 bill...

Jazz Pharmaceuticals Plc Records Impressive 3.347% Surge in Revenues During Latest Fiscal Period

Jazz Pharmaceuticals plc, a major player in the pharmaceutical industry, has demonstrated impressive growth and financial performance in the recent quarter. In the period from July to September 2023, the company's income turned positive at $2.14 per share, compared to a loss of $0.31 per share during the same period last year. This marks a significant improvement and a boost of 40.79% in earnings per share (EPS) from the preceding reporting season.
Furthermore, Jazz Pharmaceuticals has shown a modest revenue increase of 3.347%, reaching $972.14 million compared to $940.65 million in the corresponding reporting period last year. Sequentially, the company experienced a 1.548% growth in revenue from $957.32...

Jazz Pharmaceuticals Plc Surpasses Expectations with Phenomenal Profitability Surge in Q2 2023

Jazz Pharmaceuticals Plc,...

Jazz Pharmaceuticals Plc: Revenue Plummets by 41%, But Bounces Back with a Profitable Turnaround

Jazz Pharmaceuticals Plc is facing a challenge in terms of revenue per employee, as it fell on a trailing twelve month basis to $2,334,002. Despite this decline, the productivity of the company's employees remained above the company average. The company currently has 1,720 employees, but among its peers in the Healthcare sector, employees of 18 other companies have achieved higher revenue per employee.
The overall ranking of Jazz Pharmaceuticals Plc has also deteriorated compared to the fourth quarter of 2022, falling to 18. However, there is good news for the company in terms of the first quarter of the 2023 earnings season. JAZZ ...


Date modified: 2024-02-29T17:21:10+00:00





Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com